ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 04/26/23

Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib Company also announces collaborations with Foundation Medicine and R...

Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy combination study, including data on CCNE1 amplification and / or Cyclin E1 expression,...

Gainers: A-Mark Precious Metals ( AMRK ) +6% . Absci  ( ABSI ) +5% . Verve Therapeutics ( VERV ) +5% . Coherus BioSciences ( CHRS ) +5% . SouthState  ( SSB ) +4% . Losers: Cytek Biosciences ( CTKB ) -12% . 2U ...

On track to declare monotherapy RP2D for potentially first-in-class/best-in-class Wee1 inhibitor, azenosertib (ZN-c3), and provide program updates and potential paths to registration in 1H 2023 Pursuing Cyclin E1 as a patient enrichment strategy for azenosertib monotherapy in ovarian ca...

Clinical-stage biopharmaceutical company, Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) appointed of Iris Roth, PhD, as COO. Dr. Roth joins Zentalis with over two decades of biopharmaceutical experience building and executing clinical and operational strategies, successfully...

NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of...

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (“Zentalis” or the “Company”). The investigations concern whether certain of the Zentalis’ officers and direct...

Zentalis Pharmaceuticals press release ( NASDAQ: ZNTL ): Q3 GAAP EPS of -$0.96 beats by $0.25 . As of September 30, 2022, Zentalis had cash, cash equivalents and marketable securities of $421.7 million. The Company believes that its existing cash, cash equivalents ...

Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from monotherapy Phase 2 USC trial announced today Identified Cyclin E driven high-gra...

NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer...